A Phase 3 clinical trial involving goserelin changed status as of September 25, 2026. The trial, registered as NCT06447623, is titled "Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer." Its current status is listed as active, not recruiting.
The study is designated as a Phase 3 trial. According to the registry entry, this phase indicates a later-stage clinical investigation. No results have been posted for this trial in the data provided. The status update reflects only that recruitment has closed and the trial is continuing, not that any outcomes have been determined or reported.
This update pertains to a registered study evaluating a treatment combination in a specific breast cancer subtype. Details regarding trial design, endpoints, or findings beyond the status and phase are not included in this brief. Readers seeking further specifics on trial methodology or eligibility should consult the official registry listing directly.
For additional background on goserelin, its approved uses, and general context, readers can refer to the compound overview.